Harrow announced the relaunch of Triesence, a preservative-free synthetic corticosteroid, according to a press release.
Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL is FDA approved for ocular inflammatory conditions unresponsive to topical corticosteroids as well as for visualization during vitrectomy. It was on the FDA drug shortage list for more than 5 years, and inventory has been depleted for 2 years, the release said.
“We are very excited to have brought Triesence back to the U.S. market, providing ophthalmologists access to a trusted FDA-approved product that